drugset
drugset / Trial / NCT01245530

An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia

NCT01245530 ↗

Phase 3 Completed 280 enrolled Whanin Pharmaceutical Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of two fixed dose (1200mg/day, 1600mg/day) of INM-176 (a drug of treating dementia) comparing with donepezil for treatment for patients with Alzheimer type dementia.

Timeline

Start
2008-06
Primary completion
2011-02
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Donepezil Small molecule 5 mg Oral
Comparator Donepezil Small molecule 10 mg Oral
Subject INM176 Traditional medicine (herbal / TCM) 1200 mg Oral
Subject INM176 Traditional medicine (herbal / TCM) 1600 mg Oral

Indications

Alzheimer disease